{
    "nctId": "NCT01300871",
    "briefTitle": "Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer",
    "officialTitle": "Alopecia Secondary to Endocrine Therapy in Postmenopausal Women With Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Severity of Alopecia Tool (SALT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women\n* Diagnosed with hormone-receptor positive breast cancer\n* Commenced adjuvant endocrine therapy \u2265 3 months ago, specifically Tamoxifen, Anastrozole, Exemestane, and/or Letrozole\n* Good command of the English language\n* Under the care of a medical oncologist at Princess Margaret Hospital\n\nExclusion Criteria:\n\n* Previously received chemotherapy\n* Recurrent and/or metastatic disease\n* History of endocrine, dermatology, or immune system disorders known to alter hair growth (ie. Hypothyroidism and iron deficiency)",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}